Search Result

Results for "

PPARα/γ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) Adenosine Receptor (1) Akt (1) Amyloid-β (2) Antibiotic (2) Bacterial (3) COX (6) Endogenous Metabolite (1) ERK (3) Estrogen Receptor/ERR (1) FABP (2) Fatty Acid Synthase (FASN) (1) Ferroptosis (1) Free Fatty Acid Receptor (3) Fungal (3) GLUT (1) Glycosidase (1) HIF/HIF Prolyl-Hydroxylase (2) Interleukin Related (2) Isotope-Labeled Compounds (6) JNK (2) Keap1-Nrf2 (1) Ligands for Target Protein for PROTAC (1) Lipoxygenase (1) NF-κB (2) NO Synthase (3) PGE synthase (1) Phosphatase (1) PPAR (90) RAR/RXR (2) Reference Standards (13) TGF-beta/Smad (2) TNF Receptor (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (18) Endocrinology (1) Infection (4) Inflammation/Immunology (23) Metabolic Disease (75) Neurological Disease (1)

By Targets:

17β-HSD (1)

Adenosine Receptor (1)

Akt (1)

Amyloid-β (2)

Antibiotic (2)

Bacterial (3)

COX (6)

Endogenous Metabolite (1)

ERK (3)

Estrogen Receptor/ERR (1)

FABP (2)

Fatty Acid Synthase (FASN) (1)

Ferroptosis (1)

Free Fatty Acid Receptor (3)

Fungal (3)

GLUT (1)

Glycosidase (1)

HIF/HIF Prolyl-Hydroxylase (2)

Interleukin Related (2)

Isotope-Labeled Compounds (6)

JNK (2)

Keap1-Nrf2 (1)

Ligands for Target Protein for PROTAC (1)

Lipoxygenase (1)

NF-κB (2)

NO Synthase (3)

PGE synthase (1)

Phosphatase (1)

PPAR (90)

RAR/RXR (2)

Reference Standards (13)

TGF-beta/Smad (2)

TNF Receptor (1)

By Research Areas:

Cancer (15)

Cardiovascular Disease (18)

Endocrinology (1)

Infection (4)

Inflammation/Immunology (23)

Metabolic Disease (75)

Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-16578

GW9662 Maximum Cited Publications 208 Publications Verification	PPAR	Cancer
GW9662 is a potent and selective PPARγ antagonist with an IC₅₀ of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.

HY-16995

Pirinixic acid 30+ Cited Publications Wy-14643	PPAR	Metabolic Disease Inflammation/Immunology
Pirinixic acid (Wy-14643) is a potent agonist of *PPARα, with EC₅₀s of 0.63 μM, 32 μM for murine PPARα* and PPARγ, and 5.0 μM, 60 μM, 35 μM for human *PPARα, PPARγ and PPAR*δ, respectively.

HY-13861

GW7647 20+ Cited Publications	PPAR	Cardiovascular Disease
GW7647 is a potent *PPARα* agonist, with EC₅₀s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-B0637

Bezafibrate 10+ Cited Publications BM15075	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPAR*δ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-19522

Seladelpar 1 Publications Verification MBX-8025; RWJ-800025	PPAR	Metabolic Disease
Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC₅₀ of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .

HY-19937

Saroglitazar 5+ Cited Publications	PPAR	Metabolic Disease
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-13928

GW0742 15+ Cited Publications GW610742	PPAR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 is a potent PPARβ and PPARδ agonist, with an IC₅₀ of 1 nM for human PPARδ in binding assay, and EC₅₀s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.

HY-17444

Tesaglitazar	PPAR	Metabolic Disease Cancer
Tesaglitazar is a dual-target *PPARα/γ* agonist with an EC₅₀ of 13.4 μM for rat PPARα and 3.6 μM for human PPARα. Tesaglitazar affects lipid and glucose metabolism by activating PPARα and PPARγ receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain .

HY-106266

Chiglitazar 1 Publications Verification Carfloglitazar	PPAR	Metabolic Disease
Chiglitazar (Carfloglitazar) is a *PPARα/γ* dual agonist, with EC₅₀s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.

HY-N0234

Bavachinin Maximum Cited Publications 8 Publications Verification 7-O-Methylbavachin; Bavachinin A	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology Cancer
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-15725

CDDO-Im 10+ Cited Publications RTA-403; TP-235; CDDO-Imidazolide	Keap1-Nrf2 PPAR Ferroptosis	Cancer
CDDO-Im (RTA-403) is an activator of Nrf2 and *PPAR, with K_is of 232 and 344 nM for PPARα* and PPARγ .

HY-19937A

Saroglitazar magnesium 5+ Cited Publications	PPAR	Metabolic Disease
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-B0760

Fenofibric acid 3 Publications Verification FNF acid	PPAR COX	Metabolic Disease
Fenofibric acid, an active metabolite of fenofibrate, is a *PPAR* activitor, with EC₅₀s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC₅₀ of 48 nM.

HY-14928

Lobeglitazone	PPAR ERK JNK TGF-beta/Smad NO Synthase COX NF-κB Interleukin Related	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone is the orally active agonist for *PPAR* with EC₅₀ of 137.4 nM and 546.3 nM for PPARγ and *PPARα. Lobeglitazone is the inhibitor for ERK/JNK/Smad/NF-κB* signaling pathway. Lobeglitazone exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties .

HY-B0287

Clofibrate 4 Publications Verification	PPAR	Metabolic Disease
Clofibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, ～500 μM for murine PPARα* and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ, respectively.

HY-N6869

Dehydroabietic acid 1 Publications Verification	Antibiotic PPAR Bacterial Fungal	Infection Metabolic Disease Inflammation/Immunology Cancer
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual *PPAR-α/γ* agonist and *PPAR-γ* partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-112813

TUG-1375 4 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
TUG-1375 is an agonist of free fatty acid receptor 2 (FFA2/GPR43), with a pK_i of 6.69. TUG-1375 is inactive on FFA3, FFA4, PPARα, PPARγ, PPARδ, LXRα or LXRβ .

HY-N1029

Norathyriol 3 Publications Verification Mangiferitin	Glycosidase PPAR	Infection Inflammation/Immunology Cancer
Norathyriol (Mangiferitin) is a natural metabolite of Mangifera. Norathyriol inhibits α-glucosidase in a noncompetitive manner with an IC₅₀ of 3.12 μM . Norathyriol inhibits *PPARα, PPARβ, and PPARγ with IC₅₀*s of 92.8 µM, 102.4 µM, and 153.5 µM, respectively . Antioxidant, anticancer, antimicrobial, anti-inflammatory, anti-bacterial activities.

HY-14817

Indeglitazar PPM 204	PPAR	Metabolic Disease
Indeglitazar (PPM 204) is an orally available *PPAR* pan-agonist for all three PPARα, PPARδ and PPARγ .

HY-114263

NXT629 4 Publications Verification	PPAR	Cancer
NXT629 is a potent, selective, and competitive *PPAR-α* antagonist, with an IC₅₀ of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC₅₀s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively . NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models .

HY-U00425

PROTAC ERRα ligand 1	Ligands for Target Protein for PROTAC Estrogen Receptor/ERR	Metabolic Disease Cancer
PROTAC ERRα ligand 1 is a PROTAC target protein ligand. PROTAC ERRα ligand 1 is an orally active ERRα inverse agonist with IC₅₀ values of 0.6 μM for ERRα. PROTAC ERRα ligand 1 shows no significant activity against a panel of other nuclear receptors, including ERα ^c, ERRγ, ERβ, PPARα, PPARγ, PPARδ, and RXRα. PROTAC ERRα ligand 1 can provide enhanced insulin sensitivity in vivo. PROTAC ERRα ligand 1 can be used for metabolic diseases research, such as type 2 diabetes and obesity .

HY-10678

BMS-687453 3 Publications Verification	PPAR	Cardiovascular Disease
BMS-687453 is a potent and selective *PPARα* agonist, with an EC₅₀ and IC₅₀ of 10 nM and 260 nM for human *PPARα* and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.

HY-17445

Muraglitazar BMS-298585	PPAR	Metabolic Disease
Muraglitazar is a **PPAR α/γ** dual agonist for the research of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα (EC₅₀ = 320 nM) and PPARγ(EC₅₀ = 110 nM) .

HY-100277

Mifobate 1 Publications Verification SR-202	PPAR	Metabolic Disease
Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC₅₀=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects .

HY-106278

GW 590735 1 Publications Verification	PPAR	Metabolic Disease
GW 590735 is a potent and selective *PPARα* agonist. GW 590735 showsEC₅₀=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .

HY-16421

Ragaglitazar (-)-DRF 2725; NNC 61-0029	PPAR	Metabolic Disease
Ragaglitazar is a *PPARα* and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

HY-108523

LG100754 UVI 2112	RAR/RXR	Metabolic Disease
LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and *RXR:PPARγ* heterodimers. LG100754 is an insulin sensitizer that functions through RXR .

HY-19522A

Seladelpar sodium 1 Publications Verification MBX-8025 sodium; RWJ-800025 sodium	PPAR	Metabolic Disease Inflammation/Immunology
Seladelpar (MBX-8025) sodium salt is an orally active, potent and specific PPARδ agonist with an EC₅₀ of 2 nM. Seladelpar sodium salt shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar sodium salt hydrochloride can be used for the study of primary biliary cholangitis .

HY-143239

PPARα/γ agonist 1	PPAR	Metabolic Disease
PPARα/γ agonist 1 (compound 5b) is a potent and dual *PPARα/γ* partial agonist with EC₅₀ values of 28 nM and 69 nM for PPARα and PPARγ, respectively. PPARα/γ agonist 1 is a promising prototype for dyslipidemia and diabetes research .

HY-14928A

Lobeglitazone sulfate	PPAR ERK JNK TGF-beta/Smad NO Synthase COX NF-κB Interleukin Related	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Lobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate is the orally active agonist for *PPAR* with EC₅₀ of 137.4 nM and 546.3 nM for PPARγ and *PPARα. Lobeglitazone sulfate is the inhibitor for ERK/JNK/Smad/NF-κB* signaling pathway. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties .

HY-B0760S

Fenofibric acid-d6	PPAR COX	Metabolic Disease
Fenofibric acid-d₆ (FNF acid-d6) is the deuterium labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 µM, 1.47 µM, and 1.06 µM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.

HY-W109613

Methyl dehydroabietate	Bacterial PPAR Fungal	Infection Metabolic Disease
Methyl dehydroabietate is an orally active resin acid. Methyl dehydroabietate disrupts microbial cell walls and exhibits significant antibacterial activity. Methyl dehydroabietate induces the expression of *PPARα* in the liver and PPARγ in adipose tissue, and promotes adipocyte differentiation. Methyl dehydroabietate improves insulin resistance, reduces TNFα levels, and alleviates adipocyte hypertrophy and hepatic steatosis in obese mice. Methyl dehydroabietate can be used in research related to obesity, insulin resistance and hepatic steatosis .

HY-N9333

Wistin	PPAR	Metabolic Disease Cancer
Wistin, isolated from Caragana sinica roots, is a *PPARα* and PPARγ agonist .

HY-110118

Edaglitazone	PPAR	Metabolic Disease
Edaglitazone is a potent, selective and orally active PPARγ agonist, with EC₅₀s of 35.6 nM and 1053 nM for *PPARα* and PPARγ, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity .

HY-108571

CP-775146	PPAR	Cardiovascular Disease Metabolic Disease
CP-775146 is a selective *PPARα* agonist (K_i of 24.5 nM) that binds strongly to the PPARα ligand. CP-775146 has no observable affinity for PPARβ and PPARγ.CP-775146 shows hypolipidemic activity. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway .

HY-B0760R

Fenofibric acid (Standard) 3 Publications Verification FNF acid (Standard)	Reference Standards PPAR COX	Metabolic Disease
Fenofibric acid (Standard) is the analytical standard of Fenofibric acid. This product is intended for research and analytical applications. Fenofibric acid, an active metabolite of fenofibrate, is a *PPAR* activitor, with EC₅₀s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC₅₀ of 48 nM.

HY-168376

9(10)-Nitrooleate 9(10)-Nitrated oleic acid	PPAR ERK Akt NO Synthase	Metabolic Disease Inflammation/Immunology
9 (10)-Nitrooleate (9(10)-Nitrated oleic acid) is an endogenous lipid signaling mediator with vasoprotective effects. 9 (10)-Nitrooleate enhances enzymatic activity and improves nitric oxide bioavailability by inducing phosphorylation of Akt and ERK1/2, regulating the multi-site phosphorylation status of eNOS and optimizing its interaction with Hsp90. 9 (10)-Nitrooleate also activates PPARα, PPARδ and PPARγ receptors, thereby regulating adipogenesis, glucose uptake and inflammation-related gene expression, and exhibits immunosuppressive effects by inhibiting neutrophil migration and cytokine secretion. 9 (10)-Nitrooleate is widely used in studies of sepsis and related inflammatory diseases .

HY-B0637S

Bezafibrate-d6	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-163547

PPAR agonist 5	PPAR	Inflammation/Immunology
PPAR agonist 5 (compound 4b) is a potent *PPAR* agonist with EC₅₀ values of 3.20, 1.51, 1.92 µM for PPARα, PPARβ/δ, PPARγ, respectively. PPAR agonist 5 shows anti-inflammatory effect .

HY-144111

PPARα/δ agonist 1	PPAR	Inflammation/Immunology
PPARα/δ agonist 1 is a potent PPARα/PPARδ dual agonist (PPARα EC₅₀=7.0 nM; PPARδ EC₅₀=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC₅₀=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .

HY-111140

YS121	PGE synthase Lipoxygenase PPAR	Inflammation/Immunology
YS121 is a dual inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1; IC₅₀ = 3.4 μM) and 5-lipoxygenase (5-LOX; IC₅₀ = 6.5 μM). YS121 exhibits direct, reversible, and specific binding to mPGES-1 (K_D = 10-14 μM) . YS121 dose-dependently reduces PGE₂ production with an EC₅₀ of 12 μM in IL-1β-stimulated A549 cells . YS121 (compound 9) activates *PPAR-α and -γ (EC₅₀* = 1 and 3.6 μM, respectively) . YS121 exhibits anti-inflammatory efficiency in human whole blood as well as in vivo. YS121 can be used for pleurisy research .

HY-B0287R

Clofibrate (Standard) 4 Publications Verification	Reference Standards PPAR	Metabolic Disease
Clofibrate (Standard) is the analytical standard of Clofibrate. This product is intended for research and analytical applications. Clofibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, ～500 μM for murine PPARα* and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ, respectively.

HY-19848

Cevoglitazar LBM-642	PPAR	Metabolic Disease
Cevoglitazar (LBM-642) is an orally active and highly potent *PPARα* and PPARγ dual agonist. Cevoglitazar can reduce food intake, body weight, and fasting plasma insulin in obese mice and cynomolgus monkeys. Cevoglitazar has the potential for diabetes and obesity-related disorders research .

HY-Y1624

1,1'-(Azodicarbonyl)-dipiperidine ADDP; SR 4077	Free Fatty Acid Receptor PPAR	Metabolic Disease
1,1'-(Azodicarbonyl)-dipiperidine (ADDP) can be used in the condensation reaction of alcohols with acidic compounds. 1,1'-(Azodicarbonyl)-dipiperidine can also be used in the synthesis of GPR120 agonists with antidiabetic activity, as well as the synthesis of triple agonists for *PPARα, PPARγ, and PPAR*δ. 1,1'-(Azodicarbonyl)-dipiperidine can be used in metabolic disease research .

HY-121448

GW409544	PPAR	Cardiovascular Disease Metabolic Disease
GW409544 is a potent *PPARα* and PPARγ activator, with EC₅₀ values of 2.3 nM and 0.28 nM for *PPARα* and PPARγ, respectively. GW409544 can be used for the research of metabolic and cardiovascular diseases .

HY-17618A

Rac-Pemafibrate Rac-K13675	PPAR	Inflammation/Immunology
Pemafibrate racemate (K13675 racemate) is the racemate of pemafibrate, and activates *PPARα* activity, with EC₅₀s of 1 nM, >10 μM and 1.7 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.

HY-14728S

Deutaleglitazar Aleglitazar-d₂; R1439-d₂; RO0728804-d₂	PPAR	Others
Deutaleglitazar (Aleglitazar-d₂) is a agonist of dual peroxisome proliferatory activating receptor (PPARα and PPARγ) .

HY-101649

Imiglitazar TAK-559	PPAR	Cardiovascular Disease
Imiglitazar (TAK559) is a potent and dual human *PPARα* and PPARγ1 agonist with EC₅₀ values of 67 and 31 nM.

HY-106266B

Chiglitazar sodium 1 Publications Verification Carfloglitazar sodium	PPAR	Metabolic Disease
Chiglitazar (Carfloglitazar) is a *PPARα/γ* dual agonist, with EC₅₀s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.

HY-U00340

PPAR agonist 1	PPAR	Metabolic Disease
PPAR agonist 1 is an agonist of *PPAR α* and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.

Cat. No.	상품명	Category	Target	Chemical Structure

HY-N0234

Bavachinin Maximum Cited Publications 8 Publications Verification 7-O-Methylbavachin; Bavachinin A	Monophenols Flavonoids Classification of Application Fields Leguminosae Flavonones Phenols Psoralea corylifolia L. Plants Inflammation/Immunology Disease Research Fields Source Classification	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-N6869

Dehydroabietic acid 1 Publications Verification	Infection Structural Classification Microorganisms other families Classification of Application Fields Anti-aging Terpenoids Diterpenoids Plants Inflammation/Immunology Disease Research Fields Source Classification	Antibiotic PPAR Bacterial Fungal
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual *PPAR-α/γ* agonist and *PPAR-γ* partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-N1029

Norathyriol 3 Publications Verification Mangiferitin	Infection Human Gut Microbiota Metabolites Classification of Application Fields Phenols Polyphenols Mangifera indica Linn. Plants Endogenous metabolite Inflammation/Immunology Disease Research Fields Anacardiaceae Source Classification	Glycosidase PPAR
Norathyriol (Mangiferitin) is a natural metabolite of Mangifera. Norathyriol inhibits α-glucosidase in a noncompetitive manner with an IC₅₀ of 3.12 μM . Norathyriol inhibits *PPARα, PPARβ, and PPARγ with IC₅₀*s of 92.8 µM, 102.4 µM, and 153.5 µM, respectively . Antioxidant, anticancer, antimicrobial, anti-inflammatory, anti-bacterial activities.

HY-W109613

Methyl dehydroabietate	Structural Classification Pinaceae Picea abies (L.) H. Karsten Terpenoids Diterpenoids Plants Source Classification	Bacterial PPAR Fungal
Methyl dehydroabietate is an orally active resin acid. Methyl dehydroabietate disrupts microbial cell walls and exhibits significant antibacterial activity. Methyl dehydroabietate induces the expression of *PPARα* in the liver and PPARγ in adipose tissue, and promotes adipocyte differentiation. Methyl dehydroabietate improves insulin resistance, reduces TNFα levels, and alleviates adipocyte hypertrophy and hepatic steatosis in obese mice. Methyl dehydroabietate can be used in research related to obesity, insulin resistance and hepatic steatosis .

HY-N9333

Wistin	Flavonoids other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Isoflavones Source Classification	PPAR
Wistin, isolated from Caragana sinica roots, is a *PPARα* and PPARγ agonist .

HY-N6869R

Dehydroabietic acid (Standard)	Structural Classification Microorganisms other families Terpenoids Diterpenoids Plants Source Classification	Antibiotic Reference Standards PPAR Bacterial Fungal
Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-N0234R

Bavachinin (Standard) 7-O-Methylbavachin (Standard); Bavachinin A (Standard)	Structural Classification Monophenols Flavonoids Leguminosae Flavonones Phenols Psoralea corylifolia L. Plants Source Classification	Amyloid-β Reference Standards PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-N17773

Hydrangeic acid	Structural Classification Monophenols Hydrangeaceae Phenols Plants Source Classification	PPAR GLUT TNF Receptor
Hydrangeic acid is an orally effective stilbene-type glycolipid metabolism regulator that lowers blood glucose and lipids. It can be isolated from processed leaves of Hydrangea macrophylla var. thunbergii. Hydrangeic acid is associated with glycolipid metabolism and insulin sensitivity regulation. Hydrangeic acid does not directly activate PPARγ or *PPARα, but instead upregulates the mRNA expression of adiponectin, PPARγ2, GLUT4, and fatty acid-binding protein aP2, and downregulates TNF-α* mRNA expression, promoting adipogenesis, glucose uptake, and GLUT4 translocation in 3T3-L1 cells. Simultaneously, Hydrangeic acid inhibits inflammatory factor-induced NO production, exerting activity in improving insulin resistance. Hydrangeic acid can be used in research related to type 2 diabetes and does not cause liver weight gain as a side effect.

Cat. No.	상품명	Chemical Structure

HY-B0760S

Fenofibric acid-d6
Fenofibric acid-d₆ (FNF acid-d6) is the deuterium labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 µM, 1.47 µM, and 1.06 µM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.

HY-B0637S

Bezafibrate-d6
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-14728S

Deutaleglitazar
Deutaleglitazar (Aleglitazar-d₂) is a agonist of dual peroxisome proliferatory activating receptor (PPARα and PPARγ) .

HY-16578S

GW9662-d5
GW9662-d₅ is the deuterium labeled GW9662. GW9662 is a potent and selective PPARγ antagonist with an IC₅₀ of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively .

HY-B0287S

Clofibrate-d4
Clofibrate-d₄ is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.

HY-B0637S1

Bezafibrate-d4
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0637S2

Bezafibrate-13C6
Bezafibrate- ¹³C₆ (BM15075- ¹³C₆) is ¹³C labeled Bezafibrate. Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPAR*δ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-19937S1

Saroglitazar-d4
Saroglitazar-d₄ is the deuterium-labeled Saroglitazar (HY-19937). Saroglitazar-d₄ is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-B0760S1

Fenofibric acid-13C8
Fenofibric acid- ¹³C₈ (FNF acid- ¹³C₈) is ¹³C labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a *PPAR* activitor, with EC₅₀s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC₅₀ of 48 nM.

HY-B0760S2

Fenofibric acid-d4
Fenofibric acid-d₄ (FNF acid-d₄) is deuterium labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a *PPAR* activitor, with EC₅₀s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC₅₀ of 48 nM.

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고